| Rank |
Status |
Study |
| 1 |
Unknown †
|
A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
| Conditions: |
Keratoconjunctivitis Due to Adenovirus; Viral Shedding |
| Interventions: |
Drug: Zirgan; Drug: Genteal gel |
| Outcome Measures: |
Time to Viral Eradication; Development of sub-epithelial infiltrates; Degree of Bulbar conjunctival Injection; Second eye involvment |
|
| 2 |
Recruiting
|
A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis
| Condition: |
Viral Conjunctivitis |
| Interventions: |
Drug: dexamethasone 0.1%/povidone-iodine 0.4%; Drug: Artificial Tears |
| Outcome Measures: |
Conjunctival injection; Conjunctival chemosis |
|
| 3 |
Unknown †
|
Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
| Conditions: |
Ocular Surface Disease; Glaucoma |
| Interventions: |
Drug: hydroxypropylmethylcellulose; Drug: sodium hyaluronate |
| Outcome Measures: |
Ocular surface index score; Eye lid inflammation, corneal staining score, tear break up time and tear volume |
|
| 4 |
Not yet recruiting
|
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
| Conditions: |
Glaucoma; Ocular Hypertension |
| Interventions: |
Drug: bimatoprost 0.01%; Drug: travoprost 0.004%; Drug: timolol 0.5%; Drug: hypromellose 0.3% |
| Outcome Measure: |
Intraocular Pressure (IOP) in the Study Eye |
|
| 5 |
Recruiting
|
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
| Conditions: |
Glaucoma; Ocular Hypertension |
| Interventions: |
Drug: bimatoprost 0.01%; Drug: travatan 0.004%; Drug: timolol 0.5%; Drug: hypromellose 0.3% |
| Outcome Measure: |
Intraocular Pressure (IOP) in the Study Eye |
|
| 6 |
Recruiting
|
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease
| Condition: |
Niemann-Pick Disease, Type C1 |
| Intervention: |
Drug: 2-hydroxypropyl-beta-cyclodextrin |
| Outcome Measures: |
24-hydroxycholesterol Area under the curve; Hearing loss. |
|
| 7 |
Recruiting
|
The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease
| Condition: |
Dry Eye Disease |
| Interventions: |
Drug: Lotemax; Drug: Artificial Tears |
| Outcome Measures: |
In Vivo Confocal Microscopy (IVCM): Superficial corneal epithelial cells: Density, size, and hypereflectivity; In Vivo Confocal Microscopy: Corneal subbasal immune dendritiform cells: Density, size, and cell field; In Vivo Confocal Microscopy: Corneal subbasal nerves: Number and length of the main nerves and the branches; Ocular Signs: Corneal epitheliopathy; Ocular Signs: Conjunctival epitheliopathy; Ocular Signs: Tear Break Up Time (TBUT); Ocular Signs: Schirmer's Test with Anesthesia; Ocular Signs: Intraocular pressure (IOP) by measure of applanation tonometry; Ocular Symptoms: Ocular Surface Disease Index (OSDI) questionnaire; Ocular Symptoms: • Symptom Assessment iN Dry Eye (SANDE) questionnaire |
|
| 8 |
Unknown †
|
Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage
| Condition: |
Hordeolum |
| Interventions: |
Drug: neomycin sulfate, polymyxin B sulfate and gramicidin; Drug: Artificial tear |
| Outcome Measures: |
Pain scale; Mass size and duration of cure |
|
| 9 |
Recruiting
|
Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)
| Condition: |
Dry Eye |
| Interventions: |
Drug: FML 0.1% eyedrops; Drug: Liquifilm artificial tears eyedrops |
| Outcome Measures: |
Fluorescein corneal staining; Symptom Assessment in Dry Eye (SANDE) I and II questionnaire; Tear inflammatory molecule levels; Best corrected visual acuity; Biomicroscopy findings at slit lamp examination; Adverse events during the trial; Other Efficacy Measures; Intraocular pressure (IOP) and fundus examination |
|
| 10 |
Recruiting
|
Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
| Conditions: |
Keratoconjunctivitis Sicca; Dry Eye Syndrome |
| Intervention: |
Drug: dexamethasone, artificial tears |
| Outcome Measure: |
Changes in ocular surface measured by routine opthalmic dyes |
|
| 11 |
Recruiting
|
Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects
| Condition: |
Healthy |
| Interventions: |
Drug: Timoptic® 0.5%; Drug: Timophtal sine® 0.5%; Device: Genteal HA®; Device: Hylo-Comod®; Device: Thealoz® |
| Outcome Measures: |
Tear film thickness; Break up time (BUT) |
|
| 12 |
Recruiting
|
Fluorometholone as Ancillary Therapy for TT Surgery
| Conditions: |
Trichiasis; Trachoma; Bilamellar Tarsal Rotation |
| Interventions: |
Drug: Fluorometholone 0.1% ophthalmic solution; Other: Artificial tears (Placebo) |
| Outcome Measures: |
Safety assessments; Recurrence of trichiasis in the study eye |
|
| 13 |
Not yet recruiting
|
Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease
| Condition: |
Dry Eye Syndrome |
| Interventions: |
Device: Genteal HA® Eye Drops (NOVARTIS, Switzerland); Other: Physiological Sodium Chloride solution (0,9%) |
| Outcome Measures: |
Tear film thickness; Schirmer I Test; Tear Break Up Time; Ocular Surface Disease Index |
|
| 14 |
Recruiting
|
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
| Condition: |
Dry Eye Disease |
| Interventions: |
Drug: Loteprednol etabonate; Drug: Artificial Tears; Drug: Restasis |
| Outcome Measures: |
Fluorescein corneal staining scores; Lissamine green conjunctival staining |
|
| 15 |
Not yet recruiting
|
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
| Condition: |
Graves' Ophthalmopathy |
| Interventions: |
Drug: Bimatoprost; Drug: Eye drop solution |
| Outcome Measures: |
The primary endpoint of this study will be comparison of the change in ophthalmometry readings over the two 3 month treatment periods.; Change in quality of life scores on the TED quality of life questionnaire (GO-QOL); Intraocular pressures; Side effects; Health economic outcomes |
|
| 16 |
Recruiting
|
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
| Conditions: |
Sturge Weber Syndrome; Port Wine Mark |
| Interventions: |
Drug: Timolol; Drug: Preservative free artificial tear gel. |
| Outcome Measure: |
Appearance of Port-wine Mark at treatment site |
|
| 17 |
Recruiting
|
Steroids After Laser Trabeculoplasty for Glaucoma
| Condition: |
Glaucoma |
| Interventions: |
Drug: Prednisolone 1%; Drug: Diclofenac 0.1%; Drug: Artificial Tears |
| Outcome Measures: |
Intraocular pressure (IOP) lowering; Intraocular inflammation |
|
| 18 |
Unknown †
|
Aqueous Humor Dynamics and Brimonidine
| Condition: |
Intraocular Pressure |
| Interventions: |
Drug: Brimonidine; Drug: Artificial tears |
| Outcome Measure: |
Aqueous Humor Dynamics |
|
| 19 |
Recruiting
|
Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery
| Condition: |
Strabismus |
| Interventions: |
Drug: subtenons anesthetic - preservative-free bupivacaine 0.75%; Drug: topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel; Drug: topical control - 0.5 cc of Hypromellose 0.3% gel; Drug: subtenons control - 0.5 cc of Normal Saline |
| Outcome Measures: |
Average pain score over the first 30 post-operative minutes using the CHEOPS scale; Peak pain score in the first 30 minutes; Total narcotic and anti-emetic use during post-operative recovery; Negative postoperative behavior score on the PHBQ (post hospitalization behavioral questionnaire); Change in pain score |
|
| 20 |
Unknown †
|
Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
| Condition: |
Large Polyps in the Gastrointestinal Tract |
| Interventions: |
Drug: Autologous blood injection; Drug: Normal saline; Drug: HPMC |
| Outcome Measures: |
Duration of the submucosal cushion Ease of injection Ability to complete lesion removal Post-procedure complications; Ability to perform lesion removal Ability to visualize during the procedure |
|
